is ro going to stop selling semaglutide NEW RESEARCH SHOWS PATIENTS IN BODY MEMBERSHIP LOSE, 15.8% OF THEIR BODY WEIGHT ON AVERAGE IN, 12 MONTHS, #onthepen #ozempic #wegovy #semaglutide #obesity #obesitymedicine #robody Serena’s on @Ro.co, and they’re

Most patients might likely be focused only on weight reduction and stay oblivious to other metabolic and disease protection benefits

This titration approach is consistent with other incretin-based therapies and is designed to minimise gastrointestinal side effects during the initiation period

However, healthy habits can support wellbeing and gradual weight changes over time

Based on clinical trials, with the use of GLP-1 medications and lifestyle adjustments, patients can anticipate losing 10-18% of their body weight (based on the average weight loss in three 68 week clinical trials)

A decelerating trajectory is biologically plausible, but without multi-year empirical data we cannot be certain which projection most closely reflects long term real-world outcomes. But she added: Overall, the study reinforces that GLP-1 receptor agonists are unlikely to produce durable weight loss if used as short term interventions without longer term management plans